ValiRx wins €1.6m grant to develop genetics-based cancer treatment
29 August 2013
Cancer therapeutics company ValiRx plc has announced that it and
consortium member Pharmatest Services have been awarded a €1.6
million Eurostars grant to progress the pre-clinical studies of its
novel product VAL101.
VAL101 is the company’s lead candidate deriving from the GeneICE
platform for controlling 'rebellious' genes. The funds will also go
to building associated cancer models and developing further GeneICE
compounds directed at known cancer targets.
This award follows a previous Eurostars grant of €1.4 million,
the programme for which was completed earlier this year and was
accepted by both the UK Technology Strategy Board (TSB) and the
In July this year the company reported that VAL101 was
progressing from the the final preclinical proof of concept stage
with pharmacokinetics and pharmacodynamics and preliminary
toxicology studies underway at the University of Heidelberg,
The company's leading anti-cancer therapeutic product, VAL201, is
going through clinical trials in cancer patients. Results of the
trials are expected by the end of 2013.
ValiRx Chief Executive Dr Satu Vainikka said, “I am delighted to
see and grateful for continued support from the Eurostars programme.
Their grant will substantially help progress our work on VAL101 and
GeneICE, which will in turn we believe, build value”.